Francesco Maria Lavino appointed CEO of F2G Ltd

pharmafile | April 27, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |   

F2G Limited has announced that Francesco Maria Lavino has been appointed Chief Executive Officer and member of the Board of F2G.

F2G is a clinical-stage biopharmaceutical company focused on life threatening fungal diseases. Lavino has expertise in the antifungal arena, serving as AVP, Global Brand Leader in the anti-infectives portfolio at Merck & Co. and as Chief Commercial Officer of Nabriva Therapeutics.

Ian Nicholson is stepping down as CEO, after eight years with F2G, to pursue non-executive roles and will provide support to ensure an effective transition.

Patrick Vink, Chairman of F2G, commented: “We are delighted to welcome Francesco Lavino to F2G. He is a highly experienced leader with a proven track record of working to create significant value for shareholders. We believe we have a strong team in place to lead F2G into its next phase of growth.”